Logo-ipp
Submitted: 25 Sep 2018
Accepted: 10 May 2022
ePublished: 14 Jun 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2023;9(1): e94.
doi: 10.34172/ipp.2022.94
  Abstract View: 267
  PDF Download: 124

Original

Rate of clinically significant prostate cancer on repeated biopsy after a diagnosis of atypical small acinar proliferation

Mohammad Yazdani 1* ORCID logo, Payam Riahi Samani 2 ORCID logo, Hamid Mazdak 1 ORCID logo, Amid Yazdani 3 ORCID logo

1 Isfahan Urology and Kidney Transplantation Research Center, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2 Student of Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Physical Medicine and Rehabilitation, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: Correspondence to Mohammad Yazdani, Email: , Email: yazdani_k_m@yahoo.com

Abstract

Introduction: Current guidelines recommend repeat biopsy within 3-6 months for the diagnosis of atypical small acinar proliferation (ASAP) on prostate biopsy.

Objectives: We aimed to evaluate the rate of progression of ASAP to clinically significant prostate cancer on repeat biopsy specimens and determine prognostic factors associated with progression. Patients and Methods: In a retrospective study we reviewed data of patients who had a prostate biopsy in our institution from March 2014 to March 2018. Gleason grade group (GGG) was conducted for pathology reporting. Logistic regression analysis was conducted for statistical analysis.

Results: A total of 981 patients were identified of which 117 (12%) of them had a diagnosis of ASAP on their index biopsy. Out of these 16 (14%) patients underwent re-biopsy. Baseline clinicopathologic factors included a median age of 61 years, median pre-biopsy prostate-specific antigen (PSA) of 6.75 ng/mL and a mode of 1 core with ASAP. Median time interval between index and repeat biopsy was 10.5 months. The results of repeat biopsies were distributed across GGG system as follows; 12(75%) benign, 2 (12.5%) GG1, 1 (6.25%) GG2, and 1 (6.25%). We found no association between age, pre-biopsy PSA, and number of cores with ASAP, and progression of ASAP to clinically significant prostate cancer.

Conclusion: Our study showed that patients with a diagnosis of ASAP are more likely to have a benign pathology on repeat biopsy. This finding supports previous studies regarding rethinking current guidelines for utility of repeat biopsy in patients with the diagnosis of ASAP.


Citation: Yazdani M, Riahi Samani P, Mazdak H, Yazdani A. Rate of clinically significant prostate cancer on repeated biopsy after a diagnosis of atypical small acinar proliferation. Immunopathol Persa. 2023;9(1):e94. DOI:10.34172/ ipp.2022.94.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 268

Your browser does not support the canvas element.


PDF Download: 124

Your browser does not support the canvas element.